André Scheen
About
In The Last Decade
André Scheen
694 papers receiving 19.1k citations
Hit Papers
Peers
Comparison fields: 5 of 175
- Endocrinology, Diabetes and Metabolism 10.7k
- Molecular Biology 5.3k
- Surgery 4.5k
- Physiology 3.9k
- Pharmacology 3.6k
Countries citing papers authored by André Scheen
This map shows the geographic impact of André Scheen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by André Scheen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites André Scheen more than expected).
Fields of papers citing papers by André Scheen
This network shows the impact of papers produced by André Scheen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by André Scheen. The network helps show where André Scheen may publish in the future.
Co-authorship network of co-authors of André Scheen
This figure shows the co-authorship network connecting the top 25 collaborators of André Scheen. A scholar is included among the top collaborators of André Scheen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with André Scheen. André Scheen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 43 | |
| 2 | 1 | |
| 3 | 6 | |
| 4 | 4 | |
| 5 | 13 | |
| 6 | [Dapagliflozin in DELIVER : confirmation of the benefit with SGLT2 inhibitors in heart failure with preserved ejection fraction]. | 0 |
| 7 | [Semaglutide, once weekly GLP-1 receptor agonist (Ozempic®)]. | 1 |
| 8 | 11 | |
| 9 | Comment je traite ... A propos du positionnement des inhibiteurs de la DPP-4 (gliptines) dans le traitement du diabète de type 2 | 1 |
| 10 | 18 | |
| 11 | [New European guidelines for the management of dyslipidaemia in cardiovascular prevention]. | 1 |
| 12 | [Sugar: results of a Belgian observational study on the use of sitagliptin in patients with type 2 diabetes]. | 2 |
| 13 | [Suspension of the commercialization of sibutramine and rosiglitazone in Europe]. | 3 |
| 14 | 3 | |
| 15 | [Metabolically obese with normal weight individuals: an intriguing phenotype]. | 3 |
| 16 | [What is the purpose of dual or triple inhibition of the renin-angiotensin-aldosterone system?]. | 1 |
| 17 | [United Kingdom Prospective Diabetes Study (UKPDS): 10 years later]. | 7 |
| 18 | Influence du contrôle glycémique sur l’évolution de la pression artérielle pulsée chez le patient diabétique de type 1 : premiers résultats d’une étude longitudinale. | 1 |
| 19 | Contrôle pharmacologique de l’hyperglycémie postprandiale | 1 |
| 20 | Traitement du diabète de type II insulino-requérant: intérêt potentiel de l'association insuline-antidiabétiques oraux | 0 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.